What is the main impact of these new agreements on Regeneron's revenue potential?

The new agreements allow Regeneron to potentially earn tiered royalties from Novartis on future sales of certain Novartis IL-1 antibody products, such as canakinumab (ACZ885). The royalty rates range from 4% to 15% based on sales thresholds, offering a new potential revenue stream if these products are successful.

Will Regeneron have to pay royalties on its existing product, ARCALYST®?

No, Regeneron's marketed product, ARCALYST® (rilonacept) Injection for Subcutaneous Use), used for CAPS and in trials for gout, is explicitly excluded from the royalty payments Regeneron will make to Novartis. This means Regeneron retains its full revenue from ARCALYST®.

Why did Regeneron and Novartis restructure their collaboration?

The companies terminated the 2003 Collaboration Agreement to replace it with these new termination agreements. This restructuring appears to allow each company to independently advance its specific IL-1 programs, giving them greater strategic flexibility and control over their respective product development and commercialization efforts.

What are the potential risks associated with these new agreements for Regeneron?

While Regeneron can earn royalties, it also agrees to pay royalties on future sales of certain of its IL-1 blocking products. The success of these royalty-generating opportunities for both parties is dependent on the future clinical and commercial success of the respective IL-1 products, which carries inherent development and market risks.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced on June 11, 2009, the execution of two new agreements with Novartis Pharma AG and Novartis Pharmaceuticals Corporation, effective June 8, 2009. These agreements terminate and replace a previous collaboration agreement from March 2003. The primary purpose of these new agreements is to restructure the existing collaboration concerning interleukin-1 (IL-1) related product candidates, specifically Novartis's IL-1 antibody and Regeneron's second-generation IL-1 Trap. The key implications for investors revolve around the restructuring of potential revenue streams and strategic focus. Regeneron will receive tiered royalties from Novartis on future sales of certain Novartis IL-1 antibody products, including canakinumab (ACZ885), which was under regulatory review. Conversely, Regeneron has agreed to pay tiered royalties to Novartis on future sales of certain IL-1 blocking products, excluding its own marketed product ARCALYST® (rilonacept) for cryopyrin-associated periodic syndrome (CAPS). This move signals a strategic realignment, allowing each company to independently advance its respective IL-1 programs.

Key Highlights

1Regeneron and Novartis have terminated their March 2003 Collaboration Agreement, replacing it with two new termination agreements, effective June 8, 2009.
2Regeneron will receive tiered royalties from Novartis on future sales of certain Novartis IL-1 antibody products, including canakinumab (ACZ885).
3Royalty rates for Novartis's IL-1 antibody products start at 4% and can reach up to 15% on annual sales exceeding $1.5 billion.
4Regeneron has agreed to pay tiered royalties to Novartis on future sales of certain Regeneron IL-1 blocking products, excluding ARCALYST® (rilonacept).
5The royalty terms for Regeneron's covered products are identical to those for Novartis's covered products, based on aggregate, worldwide, annual net sales.
6The termination allows both companies to independently develop and commercialize their respective IL-1 antibody and IL-1 Trap product candidates.
7ARCALYST® (rilonacept) is excluded from the royalty payments Regeneron owes to Novartis, as it is already marketed by Regeneron for CAPS and in Phase 3 trials for gout.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jun 11, 2009)

Summary

Key Highlights

Frequently Asked Questions